drugset
drugset / Trial / NCT04667052

A Study to Compare Two Different Subcutaneously-administered JNJ-64304500 Formulations in Healthy Participants

NCT04667052 ↗

Phase 1 Completed 43 enrolled Janssen Research & Development, LLC
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the relative bioavailability of JNJ-64304500 after administration of two different formulations in healthy participants.

Timeline

Start
2021-01-13
Primary completion
2021-06-15
Completion
2021-06-15

Drugs

EvaluationDrugModalityDoseRoute
Subject JNJ-64304500 Unknown — Subcutaneous

Indications

No indication recorded.